CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

Franco, Jorge, Witkiewicz, Agnieszka K., Knudsen, Erik S.·2014·Oncotarget

DOI 10.18632/oncotarget.2270

Cited by (210)

Items 101–200 of 210

A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy
Benjamin Adam Weinberg, Hongkun Wang, Agnieszka Katarzyna Witkiewicz, John Lindsay Marshall, Aiwu Ruth He, Paris J. Vail, Erik S. Knudsen, Michael Jon Pishvaian · 2020 · Journal of Pancreatic Cancer
Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma
Zhichao Xue, Vivian Wai Yan Lui, Yongshu Li, Lin Jia, Chanping You, Xin Li, Wenying Piao, Hui Yuan, Pek Lan Khong, Kwok Wai Lo et al. · 2020 · Journal of Experimental & Clinical Cancer Research
Identification of targetable BRAF ΔN486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a BRAF-mutant pancreatic adenocarcinoma
Kazimierz O. Wrzeszczyński, Sadia Rahman, Mayu O. Frank, Kanika S. Arora, Minita J. Shah, Heather M. Geiger, Vanessa Felice, Dina Manaa, Esra Dikoglu, Depinder Khaira et al. · 2019 · Molecular Case Studies
Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck
Gabrielle van Caloen, Jean‐Pascal Machiels · 2019 · Current Opinion in Oncology
Breast Cancer Resistance to Cyclin-Dependent Kinases 4/6 Inhibitors: Intricacy of the Molecular Mechanisms
Bin Wang, Rui Li, Shuai Wu, Xin Liu, Jianlin Ren, Jing Li, Kaixin Bi, Yanhong Wang, Hongyan Jia · 2021 · Frontiers in Oncology
Combining CDK4/6 inhibitors ribociclib and palbociclib with cytotoxic agents does not enhance cytotoxicity
Dan Jin, Nguyen Tran, Nagheme J. Thomas, David Dinh Tran · 2019 · PLoS ONE
Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer
William Berry, Joanne Lundy, Daniel Gerald Croagh, Brendan John Jenkins · 2018 · Cancers
Palbociclib, a selective CDK4/6 inhibitor, restricts cell survival and epithelial‐mesenchymal transition in Panc‐1 and MiaPaCa‐2 pancreatic cancer cells
Özge Rencüzoğulları, Pınar Obakan Yerlikaya, Ajda Çoker Gürkan, Elif Damla Arısan, Dilek Telci · 2019 · Journal of Cellular Biochemistry
Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells
Lacey M. Litchfield, Karsten Boehnke, Manisha Brahmachary, Cecilia Mur, Bi Chen, Jennifer Rachelle Stephens, J.M. Sauder, Sonia M. Gutiérrez, Ann M. McNulty, X.S. Ye et al. · 2020 · Oncotarget
Changing the course of pancreatic cancer – Focus on recent translational advances
Milind M. Javle, Talia Golan, Anirban Maitra · 2016 · Cancer Treatment Reviews
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer
Qi Pan, Anuja Sathe, Peter C. Black, Peter Juergen Goebell, Ashish M. Kamat, Bernd J. Schmitz‐Dräger, Roman Nawroth · 2017 · Bladder Cancer
Multiplex Patient-Based Drug Response Assay in Pancreatic Ductal Adenocarcinoma
Andrew Armstrong, Muhammad R. Haque, Sina Mirbagheri, Usman Barlass, Douglas Z. Gilbert, Jaimin P. Amin, Ajaypal Singh, Ankur D Naqib, Faraz Bishehsari · 2021 · Biomedicines
Everolimus for the treatment of advanced pancreatic ductal adenocarcinoma (PDAC)
Hani M. Babiker, Michael Karass, Alejandro Recio‐Boiles, Sreenivasa Rao Chandana, Ali McBride, Daruka Mahadevan · 2019 · Expert Opinion on Investigational Drugs
A narrative review about CDK4/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer
Shidi Zhao, Haochen Zhang, Na Yang, Yang Jin · 2023 · Translational Cancer Research
Pharmacological modulation of RB1 activity mitigates resistance to neoadjuvant chemotherapy in locally advanced rectal cancer
Zhaoliang Yu, Peng Deng, Yufeng Chen, Dezheng Lin, Shini Liu, Jinghan Hong, Peiyong Guan, Jianfeng Chen, Min‐Er Zhong, Jinghong Chen et al. · 2024 · Proceedings of the National Academy of Sciences
Clinical update on K-Ras targeted therapy in gastrointestinal cancers
Shubham Pant, Joleen Marie Hubbard, Erika Martinelli, Tanios Bekaii‐Saab · 2018 · Critical Reviews in Oncology/Hematology
Breaking Cancer’s Momentum: CDK4/6 Inhibitors and the Promise of Combination Therapy
Yanbiao Liu, Seohyun Park, Yan Li · 2025 · Cancers
Efficacy and safety of abemaciclib alone and with PI3K / mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial
Elena Gabriela Chiorean, Vincent J. Picozzi, Chung‐Pin Li, Marc Peeters, Joan Maurel, Jaswinder Singh, Talia Golan, Jean‐Frédéric Blanc, Sonya C. Chapman, Anwar M. Hussain et al. · 2023 · Cancer Medicine
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations
Maryam Shariati, Kurt W. Evans, Xiaofeng Zheng, Christopher Aaron Bristow, Patrick Kwok‐Shing Ng, Yasmeen Q. Rizvi, Coya Tapia, Fei Yang, Alessandro Carugo, Timothy Paul Heffernan et al. · 2021 · Oncogene
Exceptional Response to Palbociclib in Metastatic Collecting Duct Carcinoma Bearing a CDKN2A Homozygous Deletion
Sumanta Kumar Pal, Siraj Mahamed Ali, Jeffrey S. Ross, Toni K. Choueiri, Jon Chung · 2017 · JCO Precision Oncology
Palbociclib triggers apoptosis in bladder cancer cells by Cdk2-induced Rad9-mediated reorganization of the Bak.Bcl-xl complex
Guohai Zhang, Feng-E. Ma, Liangping Li, Jingjing Li, Pingping Li, Shulan Zeng, Hongbin Sun, Erguang Li · 2019 · Biochemical Pharmacology
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
Florian G. Klein, Charlène Granier, Yuling Zhao, Qi Pan, Zhichao Tong, Jürgen E. Gschwend, Per Sonne Holm, Roman Nawroth · 2021 · Journal of Personalized Medicine
CDK4/6 Inhibitors in Pancreatobiliary Cancers: Opportunities and Challenges
Tatjana Arsenijevic, Katia Coulonval, Eric Raspé, Anne Demols, Pierre P. Roger, Jean‐Luc Van Laethem · 2023 · Cancers
Selective antitumor activity of roscovitine in head and neck cancer
Cyril S. Gary, Michael Hajek, Asel Biktasova, Gary Bellinger, Wendell Gray Yarbrough, Natalia Issaeva · 2016 · Oncotarget
The RAS-MEK-ERK pathway in low-grade serous ovarian cancer
Elizabeth H. Stover, Elizabeth K. Lee, Geoffrey Ira Shapiro, Joan S. Brugge, Ursula A. Matulonis, Joyce F. Liu · 2025 · Gynecologic Oncology
Synergistic combination of cytotoxic chemotherapy and cyclin‐dependent kinase 4/6 inhibitors in biliary tract cancers
Mansi Arora, James M. Bogenberger, Amro M. Abdelrahman, Jennifer A. Yonkus, Roberto Alva‐Ruiz, Jennifer L. Leiting, Xianfeng Chen, Pedro Luiz Serrano Usón, Chelsae Dumbauld, Alexander T. Baker et al. · 2021 · Hepatology
Combination of Abemaciclib following Eribulin Overcomes Palbociclib-Resistant Breast Cancer by Inhibiting the G2/M Cell Cycle Phase
Kamal Pandey, Nar Bahadur Katuwal, Nahee Park, Jin Hur, Young Bin Cho, Seung‐Ki Kim, Seung Ah Lee, Isaac Kim, Seung Ryeol Lee, Yong Wha Moon · 2022 · Cancers
The trend toward more target therapy in pancreatic ductal adenocarcinoma
Chiara Deiana, Margherita Agostini, Giovanni Brandi, Elisa Giovannetti · 2024 · Expert Review of Anticancer Therapy
Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies
Miguel Angel Ortega, Leonel Pekarek, Oscar Fraile‐Μartinez, Cielo García Montero, Miguel A. Sáez, Ángel Asúnsolo, Miguel Ángel Álvarez-Mon, Jorge Monserrat, Lidia Ruiz-Llorente, Natalio García‐Honduvilla et al. · 2022 · Current Oncology
Emerging kinase inhibitors for the treatment of pancreatic ductal adenocarcinoma
Udo Rudloff · 2022 · Expert Opinion on Emerging Drugs
Inhibiting CDK4/6 in pancreatic ductal adenocarcinoma via microRNA-21
Maria Mortoglou, Francesc Miralles, Rhys Richard Mould, Dipankar Sengupta, Pinar Uysal Onganer · 2023 · European Journal of Cell Biology
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai · 2024 · Cells
Combination of miR‑143 and miR‑506 reduces lung and pancreatic cancer cell growth through the downregulation of cyclin‑dependent kinases
A K M Nawshad Hossian, Gerardo Guillermo Mackenzie, George Mattheolabakis · 2021 · Oncology Reports
CDK4/6 and autophagy inhibitors synergize to suppress the growth of human head and neck squamous cell carcinomas
Ernest Duah, Nathan David Seligson, Avinash K. Persaud, Quynh Dam, Navjotsingh Pabla, James William Rocco, Junan Li, Ming Jye Poi · 2023 · Molecular Carcinogenesis
Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
Ashton Anthony Connor, Steve Gallinger · 2017 · Expert Review of Gastroenterology & Hepatology
Pharmacotherapeutic Management of Pancreatic Ductal Adenocarcinoma: Current and Emerging Concepts
Dietrich Alexander Ruess, Kıvanç Görgülü, Sonja M. Wörmann, Hana Algül · 2017 · Drugs & Aging
Cyclooxygenase-2 Influences Response to Cotargeting of MEK and CDK4/6 in a Subpopulation of Pancreatic Cancers
Joel D. Maust, Christy L. Frankowski-McGregor, Armand Bankhead, Diane M. Simeone, Judith S. Sebolt · 2018 · Molecular Cancer Therapeutics
Dual Targeting of CDK4/6 and cMET in Metastatic Uveal Melanoma
Masahiro Ohara, Kengo Saito, Ken Kageyama, Mizue Terai, Hanyin Cheng, Andrew E. Aplin, Takami Sato · 2021 · Cancers
Combination of Ribociclib and Gemcitabine for the Treatment of Medulloblastoma
Allison K. Pribnow, Barbara Jonchère, Jingjing Liu, Kyle S. Smith, Olivia Campagne, Ke Xu, Sarah Robinson, Yogesh T. Patel, Arzu Onar‐Thomas, Gang Wu et al. · 2022 · Molecular Cancer Therapeutics
Combined Inhibition of UBE2C and PLK1 Reduce Cell Proliferation and Arrest Cell Cycle by Affecting ACLY in Pan-Cancer
Keying Liang, Qian Wang, Li Qiu, Xiaocheng Gong, Zixi Chen, Haibo Zhang, Ke Ding, Yunfei Liu, Jinfen Wei, Shudai Lin et al. · 2023 · International Journal of Molecular Sciences
Microtubules play an essential role in the survival of primary acute lymphoblastic leukemia cells advancing through G1 phase
Magdalena Delgado, Timothy C. Chambers · 2018 · Cell Cycle
Synthesis and evaluation of 2′H-spiro[cyclohexane-1,3′-imidazo[1,5-a]pyridine]-1′,5′-dione derivatives as Mnk inhibitors
Ahmed M. Abdelaziz, Sunita K. C. Basnet, Saiful Islam, Manjun Li, Solomon Tadesse, Hugo Albrecht, Cobus Gerber, Mingfeng Yu, Shudong Wang · 2019 · Bioorganic & Medicinal Chemistry Letters
The Role of Precision Medicine in Pancreatic Cancer: Challenges for Targeted Therapy, Immune Modulating Treatment, Early Detection, and Less Invasive Operations
Yi Le, KhaledKyle Wong, Zhirong Qian · 2016 · Cancer translational medicine
Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4 /6 inhibition
Sabine Paternot, Eric Raspé, Clément Meiller, Maxime Tarabichi, Jean‐Baptiste Assié, Frédérick Libert, Myriam Remmelink, Xavier Bisteau, Patrick Pauwels, Yuna Blum et al. · 2022 · Molecular Oncology
Predicting anti-cancer drug combination responses with a temporal cell state network model
Deepraj Sarmah, Wesley O. Meredith, Ian K. Weber, Madison R. Price, Marc R. Birtwistle · 2023 · PLoS Computational Biology
A Perspective Study on the RTK, PI3K, B‐Raf, CDK and the Multi‐Protein Targeting in Medicinal Chemistry
Abdalla R. Mohamed, Ahmed Mahmoud El Kerdawy · 2022 · Chemistry & Biodiversity
SUZ12 promotes the malignant behavior of gastric cancer cells by CDKs
Li Guo, Caiqun Zhang · 2023 · Journal of Biochemical and Molecular Toxicology
Targeting retinoblastoma protein phosphorylation in combination with EGFR inhibition in pancreatic cancer cells
Nimmi A. Thomas, Rita G. Abraham, Brixhilda Dedi, Nancy A. Krucher · 2018 · International Journal of Oncology
[Research Progress of CDK4/6 Inhibitors in Non-small Cell Lung Cancer].
Qiong Qin, Yaoyao Ren, Diansheng Zhong · 2020 · PubMed Central
Genetic landscape of pancreatic cancer: a narrative review
Didem Oncel Yakar, Bahadır Osman Bozkirli, Guralp Onur Ceyhan · 2022 · Chinese Clinical Oncology
High-Throughput Architecture for Discovering Combination Cancer Therapeutics
Matt Gianni, Yong Wen Qin, Geert Wenes, Becca Bandstra, Anthony Paul Conley, Vivek Subbiah, Raya Leibowitz‐Amit, Sühendan Ekmekçioglu, Elizabeth Ann Grimm, Jason Roszik · 2018 · JCO Clinical Cancer Informatics
The Role of CDK4 in the Pathogenesis of Pancreatic Cancer
Emily Jiggens, Maria Mortoglou, Guy H. Grant, Pinar Uysal Onganer · 2021 · Healthcare
A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib
Weiming Fan, Chuan Wang, Xuefeng Zhong, Yating Zheng, Tingting Chen, Mengli Huang, Shu‐ying Su · 2023 · OncoTargets and Therapy
The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma
Ashleigh Parkin, Jennifer Man, Angela S. Y. Chou, Adnan M. Nagrial, Jaswinder Singh Samra, Anthony James Gill, Paul Timpson, Marina Pajic · 2018 · Diseases
A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas
Manuel M. Hidalgo, Rocio García‐Carbonero, Kian‐Huat Lim, Wells A. Messersmith, Ignacio Garrido‐Laguna, Erkut Hasan Borazanci, Andrew M. Lowy, Laura Medina, Daniel A. Laheru, Beatriz Salvador-Barberó et al. · 2022 · Cancer Research Communications
The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment
Gaoyuan Lv, Liang Zhang, Lei Gao, Jitao Cui, Ziying Liu, Bei Sun, Gang Wang, Qiushi Tang · 2022 · British Journal of Cancer
New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer
Helena Verdaguer, Alvaro Arroyo, Teresa Mercade Macarulla · 2018 · Targeted Oncology
Unexpected role of CDK4 in a G2/M checkpoint
Karen E. Sheppard, Richard B. Pearson, Ross D. Hannan · 2015 · Cell Cycle
Cyclin‐dependent kinase 4 inhibits the translational repressor 4E‐BP1 to promote cap‐dependent translation during mitosis–G1 transition
Dylan Charles Mitchell, Arya Menon, Amanda L. Garner · 2019 · FEBS Letters
Antitumoral Activity of the MEK Inhibitor Trametinib (TMT212) Alone and in Combination with the CDK4/6 Inhibitor Ribociclib (LEE011) in Neuroendocrine Tumor Cells In Vitro
Xi‐Feng Jin, Gerald Spöttl, Julian Maurer, Svenja Nölting, Christoph Josef Auernhammer · 2021 · Cancers
The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma
Hiral D. Parekh, Jason Scott Starr, Thomas J. George · 2017 · Current Treatment Options in Oncology
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy
Barbara Geerinckx, Laure-Anne Marie Nicole Teuwen, Tiffany Foo, Timon Vandamme, Annabel Smith, Marc Peeters, Timothy Jay Price · 2023 · Expert Review of Anticancer Therapy
Rhus coriaria induces autophagic and apoptotic cell death in pancreatic cancer cells
Yassine El Mahi, Zohra Nausheen Nizami, Adil Farooq Wali, Aysha Hamad Alneyadi, Mohamed Magramane, Mazoun Al Azzani, Kholoud Arafat, Samir Attoub, Ali Hussein Eid, Rabah Iratni · 2024 · Frontiers in Pharmacology
Chemosensitization and Molecular Docking Assessment of Dio-NPs on Resistant Breast Cancer Cells to Tamoxifen
Amr A. Abd-Elghany, Ebtesam A. Mohamad, Abdullah Alqarni, Mohammed Abdalla Hussein, Mohamed Mansour · 2025 · Pharmaceuticals
A Novel External Auditory Canal Squamous Cell Carcinoma Cell Line Sensitive to CDK4/6 Inhibition
Rocío García‐Marín, Virginia N. Cabal, Carmen Fernández‐Cedrón Bermejo, Cristina Riobello, Laura Suárez–Fernández, Helena Codina‐Martínez, Ainhoa Navarro‐García, Sara Lucila Lorenzo‐Guerra, Jorge García–Martínez, Blanca Vivanco et al. · 2022 · Otolaryngology
MEK Inhibitor GSK1120212-Mediated Radiosensitization of Pancreatic Cancer Cells Involves Inhibition of DNA Double-Strand Break Repair Pathways
Terence Marques Williams, A. Estrada, Moumita Chatterjee, Linlin Yang, Meredith Ann Morgan, Charles Andrew Robinson · 2015 · International Journal of Radiation Oncology*Biology*Physics
Targeted Therapies for Pancreatic Cancer
Vincent Bernard, Anirban Maitra · 2018 · Wiley eBooks
In Vitro Elucidation of Drug Combination Synergy in Treatment of Pancreatic Ductal Adenocarcinoma
Kevin T. Bush, Amélie Boichard, Igor F. Tsigelny · 2018 · Anticancer Research
Clinical significance of CCNE1 copy number gain in acral melanoma patients
Xiaowen Wu, Junya Yan, Jiayi Yu, Zhiyuan Cheng, Qian Guo, Yan Kong, Jun Guo · 2021 · Melanoma Research
Motif prediction of abemaciclib in a breast cancer cell line using ChIP-Seq data analysis
Utkarsh Deep, Ruchi Yadav · 2022 · Biomedical Research and Therapy
Future Directions in Pancreatic Cancer Therapy
David Orchard‐Webb · 2015 · Università degli Studi di Napoli Federico II
AMPK Is the Crucial Target for the CDK4/6 Inhibitors Mediated Therapeutic Responses in PANC-1 and MIA PaCa-2 Pancreatic Cancer Cell Lines
Börteçine Sevgin, Merve Coban, Özge Rencüzoğulları, Ajda Çoker Gürkan, Pınar Obakan Yerlikaya, Pinar Uysal Onganer, Elif Damla Arısan · 2021 · Stresses
Braking the cell’s cycle and invigorating T-cell immunity against pancreatic cancer
Gregory B. Lesinski · 2020 · Gut
Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity
Marc A. Hafner, Caitlin E. Mills, Kartik Subramanian, Chen Chen, Mirra Chung, Sarah A. Boswell, Robert A. Everley, Changchang Liu, Charlotte S. Walmsley, Dejan Juric et al. · 2017 · bioRxiv (Cold Spring Harbor Laboratory)
Investigation of the synergistic effect mechanism underlying sequential use of palbociclib and cisplatin through integral proteomic and glycoproteomic analysis
Lulu Yang, Bo Meng, Xiaoyun Gong, You Jiang, Xuping Shentu, Zhichao Xue · 2024 · Anti-Cancer Drugs
CCNI2 promotes pancreatic cancer through PI3K/AKT signaling pathway
Bingyang Hu, Wenzhi Zhang, Changsheng Zhang, Chonghui Li, Ning Zhang, Ke Pan, Xinlan Ge, Tao Wan · 2023 · Biomolecules and Biomedicine
Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review
Meixi Ye, Hao Xu, Jinhua Ding, Li Jiang · 2024 · Breast Cancer Targets and Therapy
CDK4/6 inhibition confers protection of normal gut epithelia against gemcitabine and the active metabolite of irinotecan
Joshua Blume, Luisa Claus, Tamara Isermann, Antje Dickmanns, Lena‐Christin Conradi, Ramona Schulz‐Heddergott, Matthias Dobbelstein · 2023 · Cell Cycle
Precision Medicine Based on Next-Generation Sequencing and Master Controllers
Katerina Dukleska, Charles J. Yeo, Michael Jon Pishvaian, Jonathan Robert Brody · 2018 · Springer eBooks
Sequence of CX-4945 and Cisplatin Administration Determines the Effectiveness of Drug Combination and Cellular Response in Cholangiocarcinoma CellsIn Vitro
Jomnarong Lertsuwan, Anyaporn Sawasdichai, Nathapol Tasnawijitwong, Kevin Gaston, Padma-Sheela Jayaraman, Jutamaad Satayavivad · 2021 · Anticancer Research
Palbociclib suppresses the cancer stem cell properties and cell proliferation through increased levels of miR-506 or miR-150 in Panc-1 and MiaPaCa-2 cells
Özge Rencüzoğulları, Elif Damla Arısan · 2022 · TURKISH JOURNAL OF BIOLOGY
Could Combinations of New and Old Drugs Enhance Tumor Cell Death?
João Marcos de Azevedo Delou, Karina Lôbo Hajdu, Helena L. Borges · 2018 · Future Oncology
Trametinib Synergized With Abemaciclib to Inhibit Tumor Growth in Human Head and Neck Squamous Cell Carcinoma Cells
Ernest Duah, Ming Jye Poi, Junan Li · 2025 · Anticancer Research
Integrated structure- and ligand-based design, synthesis, and biological evaluation of potent thiazole-based multi-kinase PI3Kα and CDK2/8 inhibitors as anticancer agents
Abdalla R. Mohamed, Ahmed Mahmoud El Kerdawy, Mohamed R. Elnagar, Mohamed Younis, Abdullah Yahya Abdullah Alzahrani, Sana Ben Moussa, Hanan Hanna Georgey, Nagwa M. Abdel Gawad, Eman R. Mohammed · 2025 · European Journal of Medicinal Chemistry
Customization of Roadmap: Human-in-the-Loop Topic Modelling Approach
Jae‐Yun Ho, Keeheon Lee · 2022 · Portland International Conference on Management of Engineering and Technology (PICMET)
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Yusuke Kojima, Reeja S. Maskey, Yuichi Machida · 2018 · Springer eBooks
Multi-Omics Profiling Establishes the Polypharmacology of FDA Approved CSK4/6 Inhibitors and Its Impact on Drug Response
Marc A. Hafner, Caitlin E. Mills, Kartik Subramanian, Chen Chen, Mirra Chung, Sarah A. Boswell, Robert A. Everley, Changchang Liu, Charlotte S. Walmsley, Dejan Juric et al. · 2018 · SSRN Electronic Journal
Molecular Therapeutics: Pancreatic Cancer
David R. Fogelman, Milind M. Javle, James L. Abbruzzese · 2015 · Wiley eBooks
CCNI2 knockdown inhibits the proliferation, apoptosis and migration of pancreatic cancer cells
Bingyang Hu, Wenzhi Zhang, Changsheng Zhang, Chonghui Li, Ning Zhang, Ke Pan, Xinlan Ge, Tao Wan · 2020
Targeting MDM2, the antagonist of the tumor suppressor p53
Anusha Sriraman · 2018
Cell Cycle Machinery and Its Alterations in Pancreatic Cancer
Yusuke Kojima, Reeja S. Maskey, Yuichi Machida · 2017 · Springer eBooks
Precision Medicine Based on Next Generation Sequencing and Master Controllers
Katerina Dukleska, Charles J. Yeo, Michael Jon Pishvaian, Jonathan Robert Brody · 2017 · Springer eBooks
Frequency of CDK2 , CCNE1 Copy Number Variation in Acral Melanoma and Implications for CDK Inhibitor in Targeted Therapy
Xiaowen Wu, Junya Yan, Jiayi Yu, Jinyu Yu, Zhiyuan Cheng, Ting Yin, Qian Guo, Yihong Xie, Yan Kong, Jun Guo · 2020
CCNI2 knockdown inhibits the proliferation, apoptosis and migration of pancreatic cancer cells
Bingyang Hu, Wenzhi Zhang, Changsheng Zhang, Chonghui Li, Ning Zhang, Ke Pan, Xinlan Ge, Tao Wan · 2020
RETRACTED: Inhibition of CDK4/6 and BET suppresses pancreatic tumor growth and epithelial-to-mesenchymal transition independently of PI3K-AKT by regulating phosphorylation of GSK3β induced Wnt/β-catenin pathway
Jiangning Gu, Xiang 'Anthony' Chen, Dan Chen, Qingzhu Duan, Menghong Yin, Wenjing Qi, Chenghong Peng, Hao Chen, Ying Li, Youwei Zhu et al. · 2022 · Research Square · Retracted
Data from Functional Genomic Analysis of CDK4 and CDK6 Gene Dependency across Human Cancer Cell Lines
Zhouwei Zhang, Lior Golomb, Matthew M. Meyerson · 2023
Data from Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
Erica S. Tsang, James Thomas Topham, Joanna M. Karasinska, Michael K.C. Lee, Laura Williamson, Shehara Ramyalini Mendis, Robert Edward Denroche, Gun Ho Jang, Steve E. Kalloger, Richard A. Moore et al. · 2023
Data from Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma
Brent A. Willobee, Alexander A. Gaidarski, Austin R. Dosch, Jason A. Castellanos, Xizi Dai, Siddharth Mehra, Fanuel Messaggio, Supriya Srinivasan, Michael Nathan VanSaun, Nagaraj S. Nagathihalli et al. · 2023
Research Progress in the Related Mechanisms of Cyclin-Dependent Kinase 4 and 6 Inhibitors in the Treatment of Breast Cancer
·别克拉米斯乌尔肯 · 2023 · Advances in Clinical Medicine
Dual Inhibitors of CDK4 /6 for Treating Cancer
Peter L. Toogood · 2024 · Wiley eBooks